New Oral Therapy Doubles PFS in ESR1+ Breast Cancer: ASCO 2025
A NEW oral therapy may significantly delay disease progression in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, according to results presented at the 2025 ASCO Annual Meeting.